Neuropsychiatric manifestations of antihypertensive medications.
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects; D000342:Affective Symptoms / Q000139:chemically induced*; D000959:Antihypertensive Agents / Q000009:adverse effects*; D001581:Benzothiadiazines; D003000:Clonidine / Q000009:adverse effects; D004232:Diuretics; D005665:Furosemide / Q000009:adverse effects; D006145:Guanethidine / Q000009:adverse effects; D006801:Humans; D006830:Hydralazine / Q000009:adverse effects; D006973:Hypertension / Q000188:drug therapy; D008750:Methyldopa / Q000009:adverse effects; D011224:Prazosin / Q000009:adverse effects; D046948:Secologanin Tryptamine Alkaloids / Q000009:adverse effects; D049993:Sodium Chloride Symporter Inhibitors / Q000009:adverse effects
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D001581:Benzothiadiazines; D004232:Diuretics; D046948:Secologanin Tryptamine Alkaloids; D049993:Sodium Chloride Symporter Inhibitors; D006830:Hydralazine; D008750:Methyldopa; D005665:Furosemide; D003000:Clonidine; D011224:Prazosin; D006145:Guanethidine